Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...
Recent advancements in understanding the molecular basis of the prostaglandin D2 receptor (DP2) have significant implications for developing new anti-inflammatory and anti-allergic therapeutics.
Consider adenosine A 2A receptor antagonists, for example, which are being evaluated as an adjuvant therapy to L-dopa or D 2 receptor agonists for Parkinson's disease, based on the evidence of ...
Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
Methods To measure dopaminergic responsivity before and after long-term treatment with stimulant medication we assessed dopamine D2 receptor availability (D2R) with placebo (PL) and with intravenous ...
Consistent with these idea, blockade of prolactin by bromocriptine, a dopamine D2 receptor agonist, prevented the onset of disease in an experimental model of PPCM and appeared successful in small ...
Results: MSA-P differed significantly from PD patients in terms of decreased putaminal volume, glucose metabolism, and postsynaptic D2 receptor density. The striatal FDOPA uptake was equally impaired ...